AD – See Bredesen
A pilot study in PD patients testing a GLP-1 receptor agonist that is currently on the market as a treatment for type 2 diabetes (exendin-4, Byetta) also showed encouraging effects. Several other clinical trials are currently ongoing in AD patients, testing another GLP-1 analogue that is on the market (liraglutide, Victoza). Recently, a third GLP-1 receptor agonist has been brought to the market in Europe (Lixisenatide, Lyxumia), which also shows very promising neuroprotective effects. This review will summarise the range of these protective effects that those drugs have demonstrated. GLP-1 analogues show promise in providing novel treatments that may be protective or even regenerative in AD and PD, something that no current drug does.
Drugs developed for treatment of diabetes show protective effects in Alzheimer’s and Parkinson’s diseases.
Drugs developed for treatment of diabetes show protective effects inAlzheimer’s and Parkinson’s diseases – full text review
See Ronda Patrick
related treatment option for PD see https://1.getmanaged.online/nly01-halts-pd/